Loading…

Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis

IntroductionHypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardio...

Full description

Saved in:
Bibliographic Details
Published in:High blood pressure & cardiovascular prevention 2022-11, Vol.29 (6), p.565-576
Main Authors: Mostafa, Sadek, Shabana, Hosam, Khalil, Farag, Mancy, Ismail Mohamed El, Zedan, Hendawy Abdel-Moety, Elmoursi, Ahmed, Ramadan, Ibrahim Ghounim, Mohamed, Saad El Deen, Kassem, Arafat, Kamel, Islam Shawky
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c282t-5276260048f9557750bf271de4985dda938ee3f3b8d72385498f66192977a1d63
cites
container_end_page 576
container_issue 6
container_start_page 565
container_title High blood pressure & cardiovascular prevention
container_volume 29
creator Mostafa, Sadek
Shabana, Hosam
Khalil, Farag
Mancy, Ismail Mohamed El
Zedan, Hendawy Abdel-Moety
Elmoursi, Ahmed
Ramadan, Ibrahim Ghounim
Mohamed, Saad El Deen
Kassem, Arafat
Kamel, Islam Shawky
description IntroductionHypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.AimTo evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.MethodsWe searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.ResultsWe included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P < 0.0001), (MD = 11.90 [8.45, 15.35], P < 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P < 0.001)ConclusionThe use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.
doi_str_mv 10.1007/s40292-022-00544-3
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2933477131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933477131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-5276260048f9557750bf271de4985dda938ee3f3b8d72385498f66192977a1d63</originalsourceid><addsrcrecordid>eNotj01OwzAQhS0EEqVwAVaWWLv1TxLHy6gUitQKRMu6cuMxdZU6IXaLchDuS1pYjN5oRu99MwjdMzpilMpxSChXnFDeF02ThIgLNGBMKsJUnl6eek6JyqW6Rjch7CjlUiVqgH6mR10ddHS1x7XFcQt4qS3EDmtv8NRaV-qyO60eD7rCqy20uunwG7TOm7ppXTUu9lVtXOM8YOfPCQvt9SfswceTcdY10EbwoWeMcIGXXYiw75Elfoejg-8zagFRk8Lrqgsu3KIrq6sAd_86RB9P09VkRuavzy-TYk5KnvNIUi4znlGa5FalqZQp3VgumYGkf9oYrUQOIKzY5EZykaf92GYZU1xJqZnJxBA9_OU2bf11gBDXu_rQ9keENVdCJFIywcQvJOBo_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933477131</pqid></control><display><type>article</type><title>Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis</title><source>Springer Nature</source><source>Alma/SFX Local Collection</source><creator>Mostafa, Sadek ; Shabana, Hosam ; Khalil, Farag ; Mancy, Ismail Mohamed El ; Zedan, Hendawy Abdel-Moety ; Elmoursi, Ahmed ; Ramadan, Ibrahim Ghounim ; Mohamed, Saad El Deen ; Kassem, Arafat ; Kamel, Islam Shawky</creator><creatorcontrib>Mostafa, Sadek ; Shabana, Hosam ; Khalil, Farag ; Mancy, Ismail Mohamed El ; Zedan, Hendawy Abdel-Moety ; Elmoursi, Ahmed ; Ramadan, Ibrahim Ghounim ; Mohamed, Saad El Deen ; Kassem, Arafat ; Kamel, Islam Shawky</creatorcontrib><description>IntroductionHypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.AimTo evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.MethodsWe searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.ResultsWe included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P &lt; 0.0001), (MD = 11.90 [8.45, 15.35], P &lt; 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P &lt; 0.001)ConclusionThe use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.</description><identifier>ISSN: 1120-9879</identifier><identifier>EISSN: 1179-1985</identifier><identifier>DOI: 10.1007/s40292-022-00544-3</identifier><language>eng</language><publisher>Auckland: Springer Nature B.V</publisher><subject>Alcohol ; Antihypertensives ; Beta blockers ; Blood pressure ; Body mass index ; Calcium ; Cardiac arrhythmia ; Cardiovascular disease ; Data collection ; Diabetes ; Drug dosages ; Edema ; Health risks ; Heart rate ; Hypertension ; Mortality ; Pharmacovigilance ; Polypharmacy ; Software</subject><ispartof>High blood pressure &amp; cardiovascular prevention, 2022-11, Vol.29 (6), p.565-576</ispartof><rights>Italian Society of Hypertension 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-5276260048f9557750bf271de4985dda938ee3f3b8d72385498f66192977a1d63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mostafa, Sadek</creatorcontrib><creatorcontrib>Shabana, Hosam</creatorcontrib><creatorcontrib>Khalil, Farag</creatorcontrib><creatorcontrib>Mancy, Ismail Mohamed El</creatorcontrib><creatorcontrib>Zedan, Hendawy Abdel-Moety</creatorcontrib><creatorcontrib>Elmoursi, Ahmed</creatorcontrib><creatorcontrib>Ramadan, Ibrahim Ghounim</creatorcontrib><creatorcontrib>Mohamed, Saad El Deen</creatorcontrib><creatorcontrib>Kassem, Arafat</creatorcontrib><creatorcontrib>Kamel, Islam Shawky</creatorcontrib><title>Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis</title><title>High blood pressure &amp; cardiovascular prevention</title><description>IntroductionHypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.AimTo evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.MethodsWe searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.ResultsWe included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P &lt; 0.0001), (MD = 11.90 [8.45, 15.35], P &lt; 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P &lt; 0.001)ConclusionThe use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.</description><subject>Alcohol</subject><subject>Antihypertensives</subject><subject>Beta blockers</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Calcium</subject><subject>Cardiac arrhythmia</subject><subject>Cardiovascular disease</subject><subject>Data collection</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Edema</subject><subject>Health risks</subject><subject>Heart rate</subject><subject>Hypertension</subject><subject>Mortality</subject><subject>Pharmacovigilance</subject><subject>Polypharmacy</subject><subject>Software</subject><issn>1120-9879</issn><issn>1179-1985</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNotj01OwzAQhS0EEqVwAVaWWLv1TxLHy6gUitQKRMu6cuMxdZU6IXaLchDuS1pYjN5oRu99MwjdMzpilMpxSChXnFDeF02ThIgLNGBMKsJUnl6eek6JyqW6Rjch7CjlUiVqgH6mR10ddHS1x7XFcQt4qS3EDmtv8NRaV-qyO60eD7rCqy20uunwG7TOm7ppXTUu9lVtXOM8YOfPCQvt9SfswceTcdY10EbwoWeMcIGXXYiw75Elfoejg-8zagFRk8Lrqgsu3KIrq6sAd_86RB9P09VkRuavzy-TYk5KnvNIUi4znlGa5FalqZQp3VgumYGkf9oYrUQOIKzY5EZykaf92GYZU1xJqZnJxBA9_OU2bf11gBDXu_rQ9keENVdCJFIywcQvJOBo_g</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Mostafa, Sadek</creator><creator>Shabana, Hosam</creator><creator>Khalil, Farag</creator><creator>Mancy, Ismail Mohamed El</creator><creator>Zedan, Hendawy Abdel-Moety</creator><creator>Elmoursi, Ahmed</creator><creator>Ramadan, Ibrahim Ghounim</creator><creator>Mohamed, Saad El Deen</creator><creator>Kassem, Arafat</creator><creator>Kamel, Islam Shawky</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20221101</creationdate><title>Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis</title><author>Mostafa, Sadek ; Shabana, Hosam ; Khalil, Farag ; Mancy, Ismail Mohamed El ; Zedan, Hendawy Abdel-Moety ; Elmoursi, Ahmed ; Ramadan, Ibrahim Ghounim ; Mohamed, Saad El Deen ; Kassem, Arafat ; Kamel, Islam Shawky</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-5276260048f9557750bf271de4985dda938ee3f3b8d72385498f66192977a1d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alcohol</topic><topic>Antihypertensives</topic><topic>Beta blockers</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Calcium</topic><topic>Cardiac arrhythmia</topic><topic>Cardiovascular disease</topic><topic>Data collection</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Edema</topic><topic>Health risks</topic><topic>Heart rate</topic><topic>Hypertension</topic><topic>Mortality</topic><topic>Pharmacovigilance</topic><topic>Polypharmacy</topic><topic>Software</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mostafa, Sadek</creatorcontrib><creatorcontrib>Shabana, Hosam</creatorcontrib><creatorcontrib>Khalil, Farag</creatorcontrib><creatorcontrib>Mancy, Ismail Mohamed El</creatorcontrib><creatorcontrib>Zedan, Hendawy Abdel-Moety</creatorcontrib><creatorcontrib>Elmoursi, Ahmed</creatorcontrib><creatorcontrib>Ramadan, Ibrahim Ghounim</creatorcontrib><creatorcontrib>Mohamed, Saad El Deen</creatorcontrib><creatorcontrib>Kassem, Arafat</creatorcontrib><creatorcontrib>Kamel, Islam Shawky</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>High blood pressure &amp; cardiovascular prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mostafa, Sadek</au><au>Shabana, Hosam</au><au>Khalil, Farag</au><au>Mancy, Ismail Mohamed El</au><au>Zedan, Hendawy Abdel-Moety</au><au>Elmoursi, Ahmed</au><au>Ramadan, Ibrahim Ghounim</au><au>Mohamed, Saad El Deen</au><au>Kassem, Arafat</au><au>Kamel, Islam Shawky</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis</atitle><jtitle>High blood pressure &amp; cardiovascular prevention</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>29</volume><issue>6</issue><spage>565</spage><epage>576</epage><pages>565-576</pages><issn>1120-9879</issn><eissn>1179-1985</eissn><abstract>IntroductionHypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.AimTo evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.MethodsWe searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.ResultsWe included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P &lt; 0.0001), (MD = 11.90 [8.45, 15.35], P &lt; 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P &lt; 0.001)ConclusionThe use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.</abstract><cop>Auckland</cop><pub>Springer Nature B.V</pub><doi>10.1007/s40292-022-00544-3</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1120-9879
ispartof High blood pressure & cardiovascular prevention, 2022-11, Vol.29 (6), p.565-576
issn 1120-9879
1179-1985
language eng
recordid cdi_proquest_journals_2933477131
source Springer Nature; Alma/SFX Local Collection
subjects Alcohol
Antihypertensives
Beta blockers
Blood pressure
Body mass index
Calcium
Cardiac arrhythmia
Cardiovascular disease
Data collection
Diabetes
Drug dosages
Edema
Health risks
Heart rate
Hypertension
Mortality
Pharmacovigilance
Polypharmacy
Software
title Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A14%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20Safety%20and%20Efficacy%20of%20Dual%20Therapy%20Perindopril/Amlodipine%20in%20the%20Management%20of%20Hypertension.%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=High%20blood%20pressure%20&%20cardiovascular%20prevention&rft.au=Mostafa,%20Sadek&rft.date=2022-11-01&rft.volume=29&rft.issue=6&rft.spage=565&rft.epage=576&rft.pages=565-576&rft.issn=1120-9879&rft.eissn=1179-1985&rft_id=info:doi/10.1007/s40292-022-00544-3&rft_dat=%3Cproquest%3E2933477131%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c282t-5276260048f9557750bf271de4985dda938ee3f3b8d72385498f66192977a1d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2933477131&rft_id=info:pmid/&rfr_iscdi=true